🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07613996
Recruiting Observational

Impact of Hyperemic State on Angio-IMR Performance

NCT07613996 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Zhongshan Hospital
Phase
Observational
Started
2026-05-04
Last updated
2026-05-29

Condition(s) studied

Coronary Artery DiseaseMicrovascular Coronary Artery Disease

Investigational drug(s) / intervention(s)

Angiography-derived IMR

Angiography-derived IMR: Unlike the reference standard "Wire-IMR," which requires the advancement of a specialized pressure-sensor guidewire into the distal coronary artery, Angio-IMR is a wire-free technology. It derives microvascular resistance indices purely through computational fluid dynamics (CFD) or specialized mathematical models based on standard coronary angiographic projections. This eliminates the risk of wire-induced vascular injury or spasm.

Study summary

The goal of this observational study is to evaluate the diagnostic performance of angiography-derived microcirculatory indices (Angio-IMR) in assessing patients with stable angina or suspected coronary artery disease. The main questions it aims to answer are:

How do the numerical values of Angio-IMR from five different software vendors change across three physiological states (resting, sub-hyperemia induced by nitroglycerin, and maximal hyperemia induced by adenosine)? Which physiological state and software algorithm provide the highest diagnostic accuracy (Area Under the Curve, AUC) for diagnosing Coronary Microvascular Disease (CMD) when compared to the gold standard wire-based IMR? Researchers will compare the Angio-IMR results calculated under the three different physiological conditions within the same patient to see how the hyperemic state impacts the performance and consistency of these non-invasive indices.

Participants will:

Undergo standard-of-care coronary angiography and physiological assessment using a pressure wire for index of microvascular resistance (Wire-IMR) as part of their clinical management.

Have their angiographic images captured at three specific time points: at rest, after intracoronary nitroglycerin, and during adenosine-induced maximal hyperemia.

Allow their de-identified imaging and clinical data to be analyzed by an independent core laboratory using five different Angio-IMR software platforms to evaluate microvascular function.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Stable angina or suspected coronary heart disease. * Scheduled for coronary angiography and physiological assessment. * Target vessel with stenosis \< 50% or 50%-90% with fractional flow reserve (FFR) \> 0.80. * Provided informed consent. Exclusion Criteria: * Hemodynamic instability (acute myocardial infarction, cardiogenic shock, severe arrhythmia). * Contraindications to angiography (e.g., end-stage renal disease). * Contraindications to adenosine (e.g., severe asthma, high-degree atrial-ventricular block). * Life expectancy \< 1 year or pregnancy. * Target vessel unsuitable for wire operation (left main lesion, severe tortuosity) or stenosis \> 90%.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Zhongshan Hospital, Fudan University Shanghai Please Select Recruiting
The First Affiliated Hospital, Sun Yat-sen University Guangzhou China Recruiting

More Shanghai Zhongshan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07613996 on ClinicalTrials.gov ↗ ← All trials in China